Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis.

In conclusion, 6 months of infliximab treatment in patients with sarcoidosis, of whom the majority benefited from the treatment, influenced immune cells in the lung and circulation differently, highlighting the importance of investigating several compartments concomitantly when evaluating treatment effects on the inflammatory activity.